Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Laurent Landais"'
Autor:
Pierre Maison-Blanche, Xavier Ligneau, Jean-François Faivre, J C Schwartz, Gary R. Mirams, Jeanne-Marie Lecomte, Rashmi R. Shah, Isabelle Berrebi-Bertrand, Laurent Landais, Philippe Robert
Publikováno v:
British Journal of Pharmacology. 174:4449-4463
Background and purpose: We evaluated the concordance of results from two sets of nonclinical cardiovascular safety studies on pitolisant. Experimental approach: Nonclinical studies envisaged both in the ICH S7B guideline and Comprehensive in vitro Pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0baf92db8dfb31cccbc65218d0614fe9
https://doi.org/10.1111/bph.14047
https://doi.org/10.1111/bph.14047
Autor:
F. d'Aniello, Christelle Anaclet, Thierry Calmels, Jeanne-Marie Lecomte, J C Schwartz, Jian-Sheng Lin, Charon Robin Ganellin, J.M. Arrang, Perrin David, Florence Gbahou, Régis Parmentier, Xavier Ligneau, Walter Schunack, J.-C. Camelin, Laurent Landais, C. Drieu la Rochelle, Holger Stark, Valerie Bertaina-Anglade, A. Rouleau, Isabelle Berrebi-Bertrand
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 320:365-375
Histamine H3 receptor inverse agonists are known to enhance the activity of histaminergic neurons in brain and thereby promote vigilance and cognition. 1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride (BF2.649) is a novel, potent, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ff326c167c6673a9f61c58a533ee265
https://doi.org/10.1124/jpet.106.111039
https://doi.org/10.1124/jpet.106.111039
Publikováno v:
Cardiovascular Drugs and Therapy. 7:233-240
The effects of the Ito blocker, tedisamil (0.1, 1.0, and 3.0 mg/kg, IV), and the IK blocker, E-4031 (0.1, 1.0, and 3.0 mg/kg, IV), on the incidence and duration of reperfusion-induced arrhythmias were compared in the anesthetized rat (n=12 per group)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90be5e380539ab7720623ca23fdd48e8
https://doi.org/10.1007/bf00878513
https://doi.org/10.1007/bf00878513
Autor:
Aude Burban, Marilyne Uguen, Perrin David, Philippe Robert, Jean-Michel Arrang, J C Schwartz, Christelle Anaclet, Johanne Piriou, Xavier Ligneau, Régis Parmentier, Jian-Sheng Lin, Laurent Landais, Emmanuel Denis
Publikováno v:
Biochemical Pharmacology
Biochemical Pharmacology, Elsevier, 2007, 73 (8), pp.1215-24. ⟨10.1016/j.bcp.2007.01.023⟩
Biochemical Pharmacology, 2007, 73 (8), pp.1215-24. ⟨10.1016/j.bcp.2007.01.023⟩
Biochemical Pharmacology / Biochemistry and Pharmacology
Biochemical Pharmacology / Biochemistry and Pharmacology, 2007, 73 (8), pp.1215-24. 〈10.1016/j.bcp.2007.01.023〉
Biochemical Pharmacology, Elsevier, 2007, 73 (8), pp.1215-24. ⟨10.1016/j.bcp.2007.01.023⟩
Biochemical Pharmacology, 2007, 73 (8), pp.1215-24. ⟨10.1016/j.bcp.2007.01.023⟩
Biochemical Pharmacology / Biochemistry and Pharmacology
Biochemical Pharmacology / Biochemistry and Pharmacology, 2007, 73 (8), pp.1215-24. 〈10.1016/j.bcp.2007.01.023〉
BF2.649, a high affinity and selective non-imidazole histamine H(3)-receptor antagonist/inverse agonist, was found to easily enter the brain after oral administration to mice: it displayed a ratio of brain/plasma levels of about 25 when considering e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca69143dce8368f515ed79bcf28861a7
https://pubmed.ncbi.nlm.nih.gov/17343831
https://pubmed.ncbi.nlm.nih.gov/17343831